Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Howard, Alan  [Clear All Filters]
Journal Article
Gooptu M, Kim HT, Howard A, Choi SW, Soiffer RJ, Antin JH, Ritz J, Cutler CS. Effect of sirolimus on immune reconstitution following myeloablative allogeneic stem-cell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clin. Biol Blood Marrow Transplant. 2019.
Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, et al. Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2019.
Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, et al. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. J Clin Oncol. 2024:JCO2300934.
Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, et al. Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma. Clin Cancer Res. 2023.
Holstein SA, J Ye C, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, C Landgren O, Munshi NC, et al. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2018.